CAR-based cell therapy: evaluation with bibliometrics and patent analysis

References

• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73. doi:10.1056/NEJMra1706169.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423–31. doi:10.1038/nature22395.
   PubMed Web of Science ®Google Scholar
• Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473–88. doi:10.1016/j.ccell.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–66. doi:10.1158/1078-0432.CCR-16-1300.
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann H-G, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265–73. doi:10.1182/blood.V100.4.1265.h81602001265_1265_1273.
   PubMed Web of Science ®Google Scholar
• Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MAA, Hannen RF, Cooper D, Marelli-Berg FM, Watt FM, Lechler RI, Maher J, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17:931–43. doi:10.1111/ajt.14185.
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56.
   PubMed Web of Science ®Google Scholar
• Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematol (United States). 2020;20:570–78.
   Google Scholar
• Daher M, Rezvani K. Outlook for new car-based therapies with a focus on car nk cells: what lies beyond car-engineered t cells in the race against cancer. Cancer Discov. 2021;11:45–58. doi:10.1158/2159-8290.CD-20-0556.
   PubMed Web of Science ®Google Scholar
• Torikai H, Reik A, Liu P-Q, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, et al. A foundation for universal T-cell based immunotherapy: t cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697–705. doi:10.1182/blood-2012-01-405365.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333-47. doi:10.1146/annurev-med-060512-150254.
   Google Scholar
• Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179–84. doi:10.1126/science.aaf6756.
   PubMed Web of Science ®Google Scholar
• Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430–33. doi:10.1038/s41586-019-1546-z.
   PubMed Web of Science ®Google Scholar
• Mao Y, Zhao C, Zheng P, Zhang X, Xu J. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy. Immunotherapy. 2021;13:177–84. doi:10.2217/imt-2020-0199.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Tan X, Pan B, Ge J, Qi K, Cheng H, Cao J, Shi M, Yan Z, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020;34:2704–07. doi:10.1038/s41375-020-0936-4.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–02. doi:10.1182/blood.2019000888.
   PubMed Web of Science ®Google Scholar
• Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: are we nearly there yet? Hum Gene Ther. 2009;20:1229–39. doi:10.1089/hum.2009.142.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Lyu L, Feng Y, Chen X, Hu Y. The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nat Biotechnol. 2020;38:1387–94.
   PubMed Web of Science ®Google Scholar
• Picanco-Castro V, Gonçalves Pereira C, Swiech K, Ribeiro Malmegrim KC, Tadeu Covas D, Silveira Porto G. Emerging CAR T cell therapies: clinical landscape and patent technological routes. Hum Vaccines Immunother. 2020;16:1424–33. doi:10.1080/21645515.2019.1689744.
   PubMed Web of Science ®Google Scholar
• Liu M, Gao Y, Yuan Y, Shi S, Yang K, Wu J, Zhang J, Tian J. Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis. Futur Oncol. 2020;16:597–612. doi:10.2217/fon-2019-0810.
   PubMed Web of Science ®Google Scholar
• Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. J Am Med Assoc. 2002;287:2847–50. doi:10.1001/jama.287.21.2847.
   PubMed Web of Science ®Google Scholar
• Boyack KW, Klavans R. Co-citation analysis, bibliographic coupling, and direct citation: which citation approach represents the research front most accurately? J Am Soc Inf Sci Technol. 2010;61:2389–404. doi:10.1002/asi.21419.
   Web of Science ®Google Scholar
• Bornmann L, Haunschild R, Mutz R. Should citations be field-normalized in evaluative bibliometrics? An empirical analysis based on propensity score matching. J Informetr. 2020;14:101098. doi:10.1016/j.joi.2020.101098.
   Web of Science ®Google Scholar
• Alcácer J, Gittelman M. Patent citations as a measure of knowledge flows: the influence of examiner citations. Rev Econ Stat. 2006;88:774–79. doi:10.1162/rest.88.4.774.
   Web of Science ®Google Scholar
• Ahmadpoor M, Jones BF. The dual frontier: patented inventions and prior scientific advance. Science. 2017;357:583–87. doi:10.1126/science.aam9527.
   PubMed Web of Science ®Google Scholar
• Coccia M, Wang L. Evolution and convergence of the patterns of international scientific collaboration. Proc Natl Acad Sci U S A. 2016;113:2057–61. doi:10.1073/pnas.1510820113.
   PubMed Web of Science ®Google Scholar
• Gittelman M, Kogut B. Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns. Manage Sci. 2003;49:366–82. doi:10.1287/mnsc.49.4.366.14420.
   Web of Science ®Google Scholar
• Lancho-Barrantes BS, Cantu-Ortiz FJ. Quantifying the publication preferences of leading research universities. Scientometrics. 2021;126:2269–310. doi:10.1007/s11192-020-03790-1.
   PubMed Web of Science ®Google Scholar
• Purkayastha A, Palmaro E, Falk-Krzesinski HJHJ, Baas J. Comparison of two article-level, field-independent citation metrics: Field-Weighted Citation Impact (FWCI) and Relative Citation Ratio (RCR). J Informetr. 2019;13:635–42. doi:10.1016/j.joi.2019.03.012.
   Web of Science ®Google Scholar
• Rodríguez-Navarro A, Brito R. Like-for-like bibliometric substitutes for peer review: advantages and limits of indicators calculated from the ep index. Res Eval. 2020;29:215–30. doi:10.1093/reseval/rvaa002.
   Web of Science ®Google Scholar
• Klavans R, Boyack KW. Research portfolio analysis and topic prominence. J Informetr. 2017;11:1158–74. doi:10.1016/j.joi.2017.10.002.
   Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130–44. doi:10.1172/JCI83092.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFV by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–58. doi:10.1038/nbt.4195.
   PubMed Web of Science ®Google Scholar
• Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Invest New Drugs. 2021;39:34–51. doi:10.1007/s10637-020-00978-3.
   PubMed Web of Science ®Google Scholar
• Jung I-Y, Kim -Y-Y, Yu H-S, Lee M, Kim S, Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 2018;78:4692–703. doi:10.1158/0008-5472.CAN-18-0030.
   PubMed Web of Science ®Google Scholar
• Georgiadis C, Preece R, Nickolay L, Etuk A, Petrova A, Ladon D, Danyi A, Humphryes-Kirilov N, Ajetunmobi A, Kim D, et al. Long terminal repeat CRISPR-CAR-Coupled “Universal” T cells mediate potent anti-leukemic effects. Mol Ther. 2018;26:1215–27. doi:10.1016/j.ymthe.2018.02.025.
   PubMed Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37. doi:10.1056/NEJMoa1817226.
   PubMed Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–700. doi:10.1182/blood-2016-04-711903.
   PubMed Web of Science ®Google Scholar
• Gou L, Gao J, Yang H, Gao C. The landscape of CAR T-cell therapy in the United States and China: a comparative analysis. Int J Cancer. 2019;144:2043–50. doi:10.1002/ijc.31924.
   PubMed Web of Science ®Google Scholar
• Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021 Apr;18(4):792–804. doi:10.1038/s41423-020-00555-x
   Google Scholar
• Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00128.
   Web of Science ®Google Scholar
• Chen J, López-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530–34. doi:10.1038/s41586-019-0985-x.
   PubMed Web of Science ®Google Scholar
• Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M, et al. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162–68. doi:10.1126/science.aav8692.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18. doi:10.1056/NEJMoa1215134.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842.
   Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531–44. doi:10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi:10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice -S-S, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–49. doi:10.1200/JCO.2014.56.2025.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar